Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.

MLA

Drai, Roman V., et al. “Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.” Clinical Pharmacology in Drug Development, vol. 11, no. 8, Aug. 2022, pp. 922–29. EBSCOhost, https://doi.org/10.1002/cpdd.1084.

APA

Drai, R. V., Karonova, T. L., Mayorov, A. Y., Makarenko, I. E., Dorotenko, A. R., Kulesh, V. S., Kovalik, V. V., & Andreeva, A. T. (2022). Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure. Clinical Pharmacology in Drug Development, 11(8), 922–929. https://doi.org/10.1002/cpdd.1084

Chicago

Drai, Roman V, Tatiana L Karonova, Alexander Y Mayorov, Igor E Makarenko, Artem R Dorotenko, Viktoria S Kulesh, Vladislav V Kovalik, and Alena T Andreeva. 2022. “Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.” Clinical Pharmacology in Drug Development 11 (8): 922–29. doi:10.1002/cpdd.1084.